OverviewSuggest Edit

Mylan is a global pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. The Company operates in two segments: Generics and Specialty. It manufactures and sells a portfolio of injectable products across various therapeutic areas. The Company markets its products to wholesalers, distributors, retail pharmacy chains, group purchasing organizations, government entities, independent pharmacies, managed care organizations, hospitals, nursing homes, and pharmacy benefit managers.

TypePublic
Founded1961
HQCanonsburg, US
Websitemylan.com
Employee Ratings3.6
Culture scoreA+

Latest Updates

Employees (est.) (Dec 2018)35,000
Job Openings129
Revenue (FY, 2019)$11.5 B
Share Price (May 2020)$17.1 (-1%)

Key People/Management at Mylan

Robert Coury

Robert Coury

Non-Executive Director
Robert Cindrich

Robert Cindrich

Non-Executive Director
JoEllen Lyons Dillon

JoEllen Lyons Dillon

Non-Executive Director
Show more

Mylan Office Locations

Mylan has offices in Canonsburg and Hatfield
Canonsburg, US (HQ)
1000 Mylan Boulevard
Hatfield, GB
Building 4, trident place, Mosquito Way
Show all (3)

Mylan Financials and Metrics

Mylan Revenue

Embed Graph
View revenue for all periods
Mylan's revenue was reported to be $11.50 b in FY, 2019
USD

Revenue (Q1, 2020)

2.6b

Gross profit (Q1, 2020)

906.1m

Gross profit margin (Q1, 2020), %

34.6%

Net income (Q1, 2020)

20.8m

EBIT (Q1, 2020)

184.7m

Market capitalization (29-May-2020)

8.8b

Closing stock price (29-May-2020)

17.1

Cash (31-Mar-2020)

572.4m

EV

20.9b
Mylan's current market capitalization is $8.8 b.
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

6.9b9.4b11.1b11.9b11.4b11.5b

Cost of goods sold

3.9b5.2b6.4b7.1b7.4b7.6b

Gross profit

3.0b4.2b4.7b4.8b4.0b3.9b

Gross profit Margin, %

44%45%42%40%35%34%
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

1.9b2.4b2.7b2.2b2.6b3.1b2.7b3.0b3.0b2.7b2.8b2.9b2.5b2.9b3.0b2.6b

Cost of goods sold

1.0b1.4b1.4b1.3b1.4b1.8b1.6b1.7b1.8b1.7b1.8b1.8b1.7b1.9b1.9b1.7b

Gross profit

830.1m1.0b1.3b907.0m1.2b1.3b1.1b1.2b1.2b984.3m962.5m1.0b805.2m932.6m1.1b906.1m

Gross profit Margin, %

44%43%49%41%46%42%40%41%39%37%34%36%32%33%36%35%
Annual
GBPFY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

288.02.5k5.9k1.8k163.032.05.1k5.2k28.9k1.2b998.8m292.1m388.1m

Accounts Receivable

975.0372.02.5k17.4k5.4k5.0k9.3k2.7b3.3b3.6b2.9b

Prepaid Expenses

596.6m756.4m766.1m518.4m

Inventories

1.7b1.7b2.0b2.5b2.5b2.6b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

626.5m933.1m847.7m480.0m696.0m352.5m16.8m

Depreciation and Amortization

516.0m566.6m1.5b1.8b2.1b2.0b

Inventories

(160.0m)(150.0m)(320.4m)(279.3m)(129.5m)(547.6m)(512.9m)

Accounts Payable

137.2m(300.0k)87.7m14.4m220.3m(96.3m)
USDY, 2020

EV/EBIT

113.4 x

EV/CFO

71.9 x

Financial Leverage

2.7 x
Show all financial metrics

Mylan Online and Social Media Presence

Embed Graph

Mylan Company Culture

  • Overall Culture

    A+

    81/100

  • CEO Rating

    B

    70/100

  • Compensation

    A+

    100/100

Learn more on Comparably

Mylan News and Updates

Mylan Invalidates Sanofi's Lantus SoloSTAR Device Patents in IPR Proceedings

HERTFORDSHIRE, England and PITTSBURGH , May 29, 2020 / / -- Mylan N.V.  (NASDAQ: MYL) today announced that the U.S. Patent and Trademark Appeal Board (PTAB) has ruled in favor of Mylan in inter partes review (IPR) proceedings finding all challenged claims of Sanofi's Lantus® SoloSTAR® device patent…

Mylan offers concessions to address EU concerns about Pfizer deal

Generic drugmaker Mylan NV has offered concessions to address European Union antitrust concerns about its bid for Pfizer's off-patent branded drugs business Upjohn, a filing on the European Commission site showed on Monday.

Drugmakers Mylan, Pfizer delay merger due to coronavirus outbreak

Drugmaker Mylan NV's merger with Pfizer Inc's off-patent branded drug unit, Upjohn, will now close in the second half of this year, the companies said on Thursday, blaming the coronavirus pandemic for the delay.

Mylan and Pfizer Provide Update Regarding Proposed Combination of Mylan and Upjohn

HERTFORDSHIRE, England and PITTSBURGH and NEW YORK, March 26, 2020 /PRNewswire/ -- Mylan N.V. (Nasdaq: MYL) and Pfizer Inc. (NYSE: PFE) today announced that due to the unprecedented circumstances surrounding the COVID-19 pandemic, including associated delays in the regulatory review...

Mylan to restart production of hydroxychloroquine

Shares of Mylan were up 6% in trading on Thursday after the drugmaker restarted production of hydroxychloroquine-sulfate tablets, which are being considered as a possible treatment for people with COVID-19. Stephen Hahn, the commissioner of the Food and Drug Administration, said Thursday at a news …

Mylan warns of possible drug shortages, financial hit due to coronavirus

Drugmaker Mylan NV said on Thursday it expects the coronavirus outbreak to impact its financial results and warned of drug shortages in case of continued spread of the virus, sending shares of the company down 3.6%.
Show more

Mylan Blogs

Mylan and Biocon Launch Fulphila®, Biosimilar Pegfilgrastim, in Canada

HERTFORDSHIRE, England , PITTSBURGH and BENGALURU, India , April 28, 2020 /CNW/ --   Mylan N.V.  and Biocon Ltd. (BSE code: 532523, NSE: BIOCON ) today announced the launch of Fulphila ® , a biosimilar to Neulasta ®   (pegfilgrastim). Fulphila is approved by Health Canada to decrease the incidence

Mylan to Release First Quarter 2020 Financial Results on May 11, 2020

HERTFORDSHIRE, England and PITTSBURGH , April 24, 2020 /PRNewswire/ -- Global pharmaceutical company Mylan N.V.  (NASDAQ: MYL) today announced that it will release its first quarter 2020 financial results on Monday, May 11 , before the open of the U.S. financial markets.

Mylan and Pfizer Provide Update Regarding Proposed Combination of Mylan and Upjohn

- Due to global impact of COVID-19 pandemic, transaction now expected to close in the second half of 2020 and Mylan's EGM moved to June 30 -

Mylan Announces Additional Efforts to Support Response to the COVID-19 Pandemic by Voluntarily Waiving its Marketing Exclusivity in the U.S. for Lopinavir/Ritonavir to Help Ensure Wider Availability to Meet Potential COVID-19 Patient Needs

HERTFORDSHIRE, England and PITTSBURGH , March 25, 2020 /PRNewswire/ --  Mylan (NASDAQ: MYL) today announced that, in its ongoing effort to support patients and public health needs in the current unprecedented circumstances surrounding the COVID-19 pandemic, Mylan has voluntarily waived its
Show more

Mylan Frequently Asked Questions

  • When was Mylan founded?

    Mylan was founded in 1961.

  • Who are Mylan key executives?

    Mylan's key executives are Robert Coury, Robert Cindrich and JoEllen Lyons Dillon.

  • How many employees does Mylan have?

    Mylan has 35,000 employees.

  • What is Mylan revenue?

    Latest Mylan annual revenue is $11.5 b.

  • What is Mylan revenue per employee?

    Latest Mylan revenue per employee is $328.6 k.

  • Who are Mylan competitors?

    Competitors of Mylan include BioMarin Pharmaceutical, Cipla and Amgen.

  • Where is Mylan headquarters?

    Mylan headquarters is located at 1000 Mylan Boulevard, Canonsburg.

  • Where are Mylan offices?

    Mylan has offices in Canonsburg and Hatfield.

  • How many offices does Mylan have?

    Mylan has 3 offices.